downgrad market perform view poorli posit
move toward value-bas care increasingli believ ownership acq aet rather
partnership open health hub necessari realiz benefit cost
trend improv without see potenti margin
distribut channel greater risk disrupt
overal healthcar system continu transit away fee-for-servic
toward value-bas care care coordin becom import compani
take holist approach care partli driver recent trend
vertic integr cvs/aet ci/esrx merger tri achiev
ingeniorx meanwhil pbm alreadi capabl
integr medic pharmaci data care coordin necessari
value-bas care healthcar model also help insul extern threat
compar peer remain focus tradit retail
pharmaci model leav view expos potenti disrupt
follow recent management meet even convinc valu
integr model found noteworthi meet
asset infrastructur improv cost trend enhanc care
coordin without aet wouldnt abl fulli realiz benefit save
larg accru payor howev aet save remain within
enterpris expect improv margin lead share gain contrast
remain reliant tradit pharmaci model driven volum
view ownership integr pharmaci pbm insur capabl one
entiti better model
despit consist report adj ep line consensu est everi quarter
hasnt alway met oper expect think indic challeng
macro environ sinc met consensu fifo gm expect
four time adj op incom expect six time despit miss consensu adj ep
larg use lever line overcom tough op
environ believ abil keep use lever like tax unsustain
slightli rais adj ep estimate lower adj ep
estimate lower pt base revis dcf
analysi impli share trade adj ep estimate
pleas see page report import disclosur
market perform rate think compani weakli posit
transit toward value-bas care rel peer other pharma
suppli chain manag care industri consolid integr medic
pharmaci data stand still reliant tradit retail pharmaci
model believ leav expos potenti disrupt also
think ownership acquisit aet rather partnership open health
hub necessari realiz benefit cost trend improv without
see potenti margin distribut channel greater risk
disrupt furthermor manag consist meet exceed adj ep
estim fare well base oper metric think indic
challeng macro environ
 y/i top-lin growth driven
growth part acquisit
alliancerx includ fep contract
 margin pressur continu part
specialti new partnership
 share repo
 y/i top-lin growth mid- high-
 y/i top-lin growth high-singl
 lower expect margin pressur
 higher expect margin pressur
 wors expect f-e margin
 share repo greater
 better expect f-e margin
 benefit disrupt cvs/aet
walgreen oper largest drugstor chain compani sell product
servic retail drugstor mail telephon on-line
channel within store walgreen sell prescript non-prescript drug
well gener merchandis includ household item conveni fresh food
person care beauti care photofinish candi primarili within retail locat
walgreen oper take clinic walgreen also oper specialti infus
respiratori servic mail servic
increas believ fall behind particularli rel
overal healthcar system continu transit away fee-for-servic
toward value-bas care care coordin becom recur theme order
achiev greater care coordin mani within pharma suppli chain manag
care industri take holist approach care integr medic
pharmaci data import compon partli driver recent
trend vertic integr need address value-bas care underlin
acquisit aet ci acquisit esrx reflect
lead player move value-bas care asset optum similarli
start format pbm ingeniorx alreadi capabl
integr medic pharmaci data pbm expand
capabl deliv care patient home recent stake kindr
care coordin necessari value-bas care healthcar
model also believ help insul compani extern threat
competit new entrant like howev date doesnt appear
path toward greater care coordin leav expos disrupt
much like esrx like would stand-alon basi howev
acquisit aet ci acquisit esrx becom obviou
valu combin entiti respect pharmaci oper
rel basi think expos potenti disrupt retail
pharmaci space particularli light amzn acquisit pillpack other
least posit becom broader healthcar compani
focu care coordin remain reliant tradit
retail pharmaci model concern us believ primari role
pharmaci dispens prescript could risk becom
commodit note recent sell-sid analyst event envis
open health hub limit detail far hard determin defens
could threat potenti disrupt furthermor open
health hub model appear center pharmaci focu drive foot
traffic volum rather improv care coordin doesnt seem
align transit occur elsewher market think continu
focu drive foot traffic evidenc wba recent announc partnership
view seem predic drive medicar part
member locat manag continu focu senior popul
prolif user pharmaceut
follow recent manag meet even convinc
valu integr model found noteworthi manag
meet current asset infrastructur
improv cost trend enhanc care coordin stand-alon basi without aet
wouldnt abl fulli realiz benefit save save larg
accru payor howev acquisit aet complet save
remain within enterpris expect improv margin lead
share gain cost save pass custom model
leverag frequent direct interact patient chang patient
behavior expect drive better outcom gener total healthcar cost
save retain aet contrast remain reliant
tradit pharmaci model driven foot traffic volum even wba
vision open healthcar hub partnership core mean drive
increment volum well rental incom view addit
open healthcar hub model retain cost trend improv
like accru payor instanc realiz benefit
improv patient health medexpress urgent care clinic locat
store even gain share arrang establish
think would becom difficult quantifi alloc save amongst two
parti view ownership integr pharmaci pbm
insur capabl one entiti better model
despit consist report adjust ep in-lin consensu estim everi
quarter hasnt alway met street expect term oper metric
particularli regard fifo gross margin reflect challeng macro
environ face due continu reimburs pressur sinc
met consensu fifo gross margin expect four time
ep expect miss penni figur
oftentim beaten adjust ep expect due lower expect tax
rate dont think sustain anniversari benefit tax
reform furthermor although manag effect drive effici
optim compani cost structur dont believ sustain
long-term either note three time miss fifo gross profit
manag abl lower sg meet exceed adjust oper incom
figur perform rel consensu
cowen compani
see two risk downgrad dont think address
long-term strateg issu posit threat disrupt retail
benefit disrupt due cvs-aet merger think disrupt
cvs-aet merger could benefici fairli common
larger complic transact leakag benefit
competitor case cvs-aet merger would like
biggest beneficiari leakag
meaning acquisit think meaning acquisit could risk
downgrad acquisit remain stake
think would accret howev dont see potenti
acquisit target larg enough profoundli advanc
regard care coordin value-bas care
slightli rais adj ep estim lower
adj ep estim lower price target
base revis dcf analysi impli share trade
adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn adjust equiti earn abc- adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust equiti earn adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust oper adjust oper chang gross oper cowen
million except per-shar data
compani report cowen compani
gross gross chang adjust oper adjust oper chang oper cowen
million except per-shar data
compani report cowen compani
gross gross chang adjust earn adjust oper adjust oper chang oper cowen
million
compani report cowen compani
asset cash account receiv current current properti intang non-curr total current liabil short-term trade account accru expens incom current long-term defer incom non-curr stockhold equiti common paid-in employe stock loan retain accumul comprehens treasuri non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end august cowen
million
compani report cowen compani
income/ loss flow oper activ depreci gain previous held equiti interest- share base compens unreal gain fair valu adjustments- defer incom invest impair chang oper asset liabil receiv current non-curr assets- account accru expens incom non-curr net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end august cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net earn net cash depreci loss allianc boot call option- sale business- defer incom stock compens incom tax save employe stock plans- chang oper asset liabil account receiv current trade account accru expens incom non-curr asset net cash provid oper flow invest activitiesaddit properti proce sale leaseback transactions- purchas short-term invest held proce short-term invest held purchas short-term invest avail sale- proce sale short-term invest avail sale- return invest restrict cash- proce sale busi intang asset acquisit net cash payment proce sale invest invest allianc boots- net cash use invest flow financ activitiesnet payment short-term borrowings- payment long-term proce financ leases- issuanc long-term stock proce relat employe stock dividend net cash provid use financ effect exchang rate chang cash cash equivalents- chang equivalentsnet decreas cash cash cash equival begin cash equival end year end august cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
number company-specif risk associ pt includ loss
share disrupt entiti wors expect reimburs pressur better
expect gener procur wbad meaning acquisit
